Want to see QURE full AI Analyst Report?
QURE Stock Chart & Stats
$17.58
-$1.39(-7.88%)
At close: 4:00 PM EST
$17.58
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$8.73 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)2.42M
Market Cap
$2.84B
Enterprise Value$2.96B
Total Cash (Recent Filing)$586.55M
Total Debt (Recent Filing)$63.32M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 04, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.51
Shares Outstanding68,012,540
10 Day Avg. Volume3,292,185
30 Day Avg. Volume2,422,111
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue163.64
Enterprise Value/Gross Profit220.70
Enterprise Value/Ebitda-22.93
Forecast
1Y Price Target
$66.33Price Target Upside277.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.63
Revenue Forecast (FY)$20.98M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For AMT-130 (accelerated Approval Pathway)FDA agreement to use three-year Phase I/II data as the primary basis for an accelerated BLA (with BLA planned for Q3 2026) materially raises the probability of earlier regulatory entry. This durable regulatory alignment shortens commercialization timelines and clarifies confirmatory study requirements.
Promising Early Efficacy And Tolerability For AMT-260Robust early seizure reductions and benign safety in the low‑dose cohort provide structural evidence the platform can deliver durable single‑dose benefit in neurology. If replicated in higher doses/confirmatory trials, this validates uniQure's AAV approach and supports longer‑term program expansion and partnerships.
Substantial Equity Capital Raise Strengthens RunwayThe sizable equity raise materially bolsters liquidity, reducing near‑term financing pressure and enabling planned regulatory filings and confirmatory trials. A stronger balance of cash versus burn supports multiyear R&D execution and lowers the odds of urgent, dilutive financings in the coming 2–6 months.
Bears Say
High And Persistent Cash BurnLarge negative operating and free cash flow is a structural weakness: sustained burn requires external financing to fund trials and operations, increasing dilution risk and dependency on capital markets or partner deals, which could limit strategic optionality over the medium term.
Modest And Volatile Revenue BaseLow recurring revenue relative to R&D and operating costs means the business is not self‑funding. Even with solid gross margin, volatile and small revenue undermines ability to absorb development spending and raises reliance on milestone, licensing or equity inflows for sustainability.
Balance-sheet Volatility And Historical Negative EquityPast periods of negative equity and large year‑to‑year swings indicate structural financing volatility. Such fluctuations can raise borrowing costs, complicate partner negotiations, and increase investor scrutiny, limiting long‑term financial flexibility despite recent capital raises.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $8.73 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $2.84B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Aug 04, 2026 which is in 29 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.865 by $0.015.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.83.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 68,012,540 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.865. Following the earnings report the stock price went up 2.321%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.33 (277.32% Upside)
$66.33 (277.32% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 89.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $966.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
192.78%
12-Months-Change
Fundamentals
Return on Equity
-145.81%
Trailing 12-Months
Asset Growth
28.63%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$66.33
▲(277.32% Upside)
Technical Analysis
Ownership Overview
2.04% Insiders
12.35% Mutual Funds
0.04% Other Institutional Investors
78.09% Public Companies and
Individual Investors